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We report a case of Lassa fever in a US traveler who 
visited rural Liberia, became ill while in country, sought med-
ical care upon return to the United States, and subsequently 
had his illness laboratory conﬁ  rmed. The patient recovered 
with supportive therapy. No secondary cases occurred.
L
assa fever is a potentially severe viral infection caused 
by  Lassa virus (family Arenaviridae, genus Arena-
virus), with an overall case-fatality rate of 1%–2% and a 
case-fatality rate of 15%–20% for hospitalized patients 
(1,2). The virus is endemic to West Africa, with the reser-
voir host being Mastomys spp. rodents (3). Person-to-per-
son transmission of Lassa virus can occur through direct 
exposure to infected blood or secretions, and instances of 
nosocomial transmission have been documented (4,5). Pri-
mary symptoms of Lassa fever are fever, headache, nausea, 
diarrhea, sore throat, and myalgia; hemorrhagic signs or 
deafness may also occur during illness (1,6).
Because the incubation period ranges from a few days 
to >2 weeks (1,5) and many symptoms are nonspeciﬁ  c, the 
potential exists for human carriage of Lassa virus to areas 
outside those to which it is endemic, putting travel com-
panions, close contacts, and healthcare providers at risk for 
secondary infection. Before 2010, ﬁ  ve instances of import-
ed Lassa virus were recorded in persons from West Africa 
to the United States. Although early instances involved sick 
persons who were airlifted to the United States for diag-
nosis and treatment (7–9), the 2 most recent occurrences 
(1989 and 2004) involved persons who were not identiﬁ  ed 
as potentially infectious until healthcare was sought in the 
United States (10,11). Here we report a case in a person 
who became infected and sick during a trip to Liberia and 
sought care upon return to the United States.
The Case
A Liberian man 47 years of age living in the United 
States traveled to Liberia in January 2010. He arrived in 
Monrovia, then spent 5 days traveling throughout Nimba 
County in north-central Liberia, bordering Guinea and 
Côte d’Ivoire. He reported sleeping nightly in his rural na-
tive village in a dwelling infested with rats and recalled 
several rat carcasses on the bedroom ﬂ  oor. On the day of 
his departure from Liberia, he developed fever, chills, joint 
pain of the knees and ankles, anorexia, sore throat, diffuse 
skin tenderness, and mild shortness of breath; he began tak-
ing amoxicillin and chloroquine before departing Liberia.
The patient’s symptoms persisted upon arrival in the 
United States, prompting him to seek medical attention on 
day 5 of his illness. When he sought treatment, he had fe-
ver of 103°F, pulse of 99 beats/min, respiratory rate of 15 
breaths/min, and blood pressure of 120/80 mm Hg (online 
Appendix Table, www.cdc.gov/EID/content/16/10/1598-
appT.htm). His physical examination was notable for pos-
terior cervical adenopathy and a palpable spleen tip (Table). 
He had no evidence of conjunctival, nasal, or oral petechi-
ae; no skin rashes; and no signs of hemorrhage or other le-
sions. Initial laboratory data showed leukopenia and throm-
bocytopenia and minimal transaminase elevations (online 
Appendix Table). Empiric malaria treatment was initiated 
upon admission and was subsequently discontinued when 
Plasmodium spp. antigen testing was negative and thick 
and thin blood smears showed no evident parasitemia. By 
the next day, mild pharyngitis with slight tonsillar exudates 
had developed. On the third hospital day, substernal chest 
pain and profuse watery diarrhea developed. Increasing 
transaminases and a slight coagulopathy were noted. Lassa 
fever was considered in the differential diagnosis; contact 
precautions and, subsequently, airborne precautions were 
taken. Because of noted clinical improvement, he was not 
given empiric intravenous ribavirin.
On day 5 of hospitalization, Lassa virus was identiﬁ  ed 
by real-time PCR by using samples collected 2 days earlier, 
and sequencing of the ampliﬁ  ed fragment yielded a unique 
sequence similar to sequences from previous Lassa virus 
isolates from Liberia. Subsequent samples conﬁ  rmed Lassa 
fever diagnosis on the basis of real-time PCR, viral culture, 
and serology (Table).
The patient’s fever resolved by day 16 of his illness. 
After 2 successive negative blood real-time PCR results, 
he was discharged from the hospital on day 21 of his ill-
ness with instructions to avoid unprotected sexual inter-
course for 2 months. No hearing abnormalities were noted 
at the time of discharge or during telephone conversations 
2 weeks and 2 months later.
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A contact investigation was undertaken by the hospital 
and local, state, federal, and international health agencies. 
Exposed persons were identiﬁ  ed as any persons who poten-
tially came into contact with the patient or his body ﬂ  uids 
during his illness. Because no contacts had direct exposure 
to body ﬂ  uids (other than the patient’s wife in Africa with 
whom he had sexual intercourse before becoming ill and 
who remained well, according to telephone follow-up with 
the patient), no patient contacts were considered high risk 
for secondary transmission (10). In total, 140 persons, in-
cluding the patient’s family in the United States, co-work-
ers, and hospital workers who had contact with him (but 
did not have direct contact with bodily ﬂ  uids) were identi-
ﬁ  ed as low-risk contacts. Health communication materials 
were developed on the basis of previous Lassa fever contact 
tracing activities (10). All hospital and community contacts 
were provided a Lassa fever fact sheet and asked to seek 
medical consultation if fever or other signs and symptoms 
of Lassa fever appeared. Upon completion of 21 days of 
follow-up, no secondary cases were identiﬁ  ed.
Conclusions
The spectrum of Lassa fever can run from asymp-
tomatic seroconversion to severe hemorrhagic fever with 
multiple organ failure and death (1,2,6). Factors supporting 
the diagnosis of Lassa fever in returning travelers include 
relevant epidemiologic exposure (travel to rural West Af-
rica), signs and symptoms consistent with Lassa fever, and 
the absence of other infectious agents that can account for 
the illness. Although this patient did not seek treatment for 
hemorrhagic signs, his fever, pharyngitis, chest pain, and 
diarrhea (1,6), as well as thrombocytopenia and elevated 
transaminases, were consistent with Lassa fever (6,12). 
Early institution of ribavirin can dramatically decrease 
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Table. Day by day symptoms and clinical information for a man 47 years of age with Lassa fever, Pennsylvania, USA, 2010* 
Date Symptoms  Examination findings
Bowel
movements Clinical information  Clinical action 
Jan 13–17   Fevers and chills, sore throat, 
arthralgias, diffuse abdominal 
pain
NA NA NA NA
Jan 18 Fevers and chills, sore throat, 
watery diarrhea, diffuse 
abdominal pain. 
Prominent parotids, 
posterior cervical 
lymphadenopathy, 
slight spleen tip 
12 Contact isolation
ordered. 
Jan 19  Fevers and chills, sore throat, 
substernal chest pain with 
inspiration and when lying 
supine, diarrhea, diffuse 
abdominal pain. Arthralgias 
resolve. 
Slight tonsillar 
exudates, slight 
spleen tip 
|18 Tests for Clostridium 
difficile, cryptosporidium, 
Giardia spp., thick and 
thin blood smears for 
malaria, Epstein-Barr 
virus, and respiratory 
virus panel; all negative 
Contact
precautions. Blood 
samples to test for 
Lassa virus drawn.
Jan 20  Fevers and chills; sore throat; 
substernal chest pain, worse 
when lying down; diarrhea. 
Abdominal pain improving. 
Slight tonsillar 
exudates, slight 
spleen tip 
3 HIV negative  EKG done, 
ribavirin requested, 
airborne
precautions
Jan 21  Fevers and chills, sore throat, 
diarrhea. Chest pain resolves. 
Abdominal pain improving. 
Slight spleen tip  5 Stool culture negative  Held off on 
ribavirin. CDC 
received
specimen.
Jan 22  Fevers and chills, sore throat. 
Diarrhea resolves. Abdominal 
pain resolves. 
Prominent
sternocleidomastoid
muscles 
NA Stopped IV fluids. 
Jan 23  Fevers and chills, sore throat  Prominent
sternocleidomastoid
muscles 
3, formed  PCR positive for Lassa 
virus 
Jan 24  Fevers and chills, sore throat  Prominent
sternocleidomastoid
muscles 
NA
Jan 25  Fevers and chills. Sore throat 
improves.
Prominent
sternocleidomastoid
muscles 
3, formed 
Jan 26  Fevers and chills. Sore throat 
improves.
Neck less prominent NA
Jan 27  Fevers and chills. Sore throat 
resolves. 
Decreased parotid 
enlargement and 
lymphadenopathy 
NA
Jan 28–29   Fevers and chills  NA
Jan 30–Feb 3  Fever resolves  NA
*NA, not available; EKG, electrocardiogram; IV, intravenous; CDC, Centers for Disease Control and Prevention. death rates among patients with severe Lassa fever if given 
within the ﬁ  rst 6 days of illness (12); therefore, empiric 
ribavirin should be considered for an ill patient suspected 
of having Lassa fever.
As in this case, early suspicion of Lassa fever should 
prompt isolation measures to avoid secondary transmis-
sion; laboratory testing should be limited to essential tests, 
and all laboratory specimens should be handled with appro-
priate biosafety precautions to avoid aerosolizing the virus 
(13). Experience in regions where Lassa virus is endemic 
suggests human-to-human transmission occurs through 
direct contact with blood and body ﬂ  uids or large-particle 
inhalation; transmission through viral aerosolization is not 
seen; and generally, when universal precautions are under-
taken, transmission is unlikely (14). Nonetheless, aerosol in 
addition to contact precautions were undertaken once Lassa 
fever was suspected, given the theoretical potential for ac-
quiring infection through inhalation of airborne virus from 
respiratory secretions or, in this case, copious diarrhea.
The patient described in this report represents the sixth 
known occurrence of Lassa fever imported to the United 
States. Clinicians treating recent travelers to West Africa 
who are febrile should obtain detailed histories from pa-
tients to determine whether they have traveled into rural 
areas in which the potential for exposure to rodents exists. 
The symptoms, signs, and laboratory abnormalities of Las-
sa fever are nonspeciﬁ  c and can overlap with other tropical 
infections. Therefore, efforts should be made to promptly 
diagnose or rule out other infectious agents in a patient 
who has the appropriate travel and exposure history so that 
further diagnostic studies and empiric therapy with ribavi-
rin can be undertaken rapidly. Moreover, as soon as Lassa 
fever is suspected, patients and their specimens should be 
handled with adequate precautions, the local health de-
partment and Centers for Disease Control and Prevention 
should be notiﬁ  ed, and specimens should be sent for spe-
ciﬁ  c diagnostic testing.
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